AffiliationDivision of Cancer Sciences, The University of Manchester, Manchester, UK
MetadataShow full item record
AbstractOver the past decade, various liquid biopsy techniques have emerged as viable alternatives to the analysis of traditional tissue biopsy samples. Such surrogate 'biopsies' offer numerous advantages, including the relative ease of obtaining serial samples and overcoming the issues of interpreting one or more small tissue samples that might not reflect the entire tumour burden. To date, the majority of research in the area of liquid biopsies has focused on blood-based biomarkers, predominantly using plasma-derived circulating tumour DNA (ctDNA). However, ctDNA can also be obtained from various non-blood sources and these might offer unique advantages over plasma ctDNA. In this Review, we discuss advances in the analysis of ctDNA from non-blood sources, focusing on urine, cerebrospinal fluid, and pleural or peritoneal fluid, but also consider other sources of ctDNA. We discuss how these alternative sources can have a distinct yet complementary role to that of blood ctDNA analysis and consider various technical aspects of non-blood ctDNA assay development. We also reflect on the settings in which non-blood ctDNA can offer distinct advantages over plasma ctDNA and explore some of the challenges associated with translating these alternative assays from academia into clinical use.
CitationTivey A, Church M, Rothwell D, Dive C, Cook N. Circulating tumour DNA - looking beyond the blood. Nature reviews Clinical oncology. 2022 Sep;19(9):600-12. PubMed PMID: 35915225. Pubmed Central PMCID: PMC9341152 Ingelheim, Biocartis, GRAIL and Merck, and has received research funding from Angle, Amgen, Astex Pharmaceuticals, AstraZeneca, Bayer, Bioven, Bristol Myers Squibb, Boehringer Ingelheim, Carrick Therapeutics, Celgene, Clearbridge Biomedics, Epigene Therapeutics, GlaxoSmithKline, Menarini, Merck AG, Neomed Therapeutics, Novartis, Roche, Taiho Oncology and Thermo Fisher Scientific. N.C. has received research funding from AstraZeneca, Avacta, Bayer, Boehringer, Eisai, Merck, Orion, Pfizer, RedX, Roche, Starpharma, Stemline Tarveda, Taiho Oncology and UCB. The other authors declare no competing interests. Epub 2022/08/02. eng.
JournalNature Reviews Clinical Oncology
- The value of cell-free DNA for molecular pathology.
- Authors: Stewart CM, Kothari PD, Mouliere F, Mair R, Somnay S, Benayed R, Zehir A, Weigelt B, Dawson SJ, Arcila ME, Berger MF, Tsui DW
- Issue date: 2018 Apr
- Analytical performance evaluation of a commercial next generation sequencing liquid biopsy platform using plasma ctDNA, reference standards, and synthetic serial dilution samples derived from normal plasma.
- Authors: Verma S, Moore MW, Ringler R, Ghosal A, Horvath K, Naef T, Anvari S, Cotter PD, Gunn S
- Issue date: 2020 Oct 1
- [Liquid biopsy in colorectal cancer : An overview of ctDNA analysis in tumour diagnostics].
- Authors: Haupts A, Roth W, Hartmann N
- Issue date: 2019 Dec
- Circulating tumor DNA: current challenges for clinical utility.
- Authors: Dang DK, Park BH
- Issue date: 2022 Jun 15
- Extending Circulating Tumor DNA Analysis to Ultralow Abundance Mutations: Techniques and Challenges.
- Authors: Rodda AE, Parker BJ, Spencer A, Corrie SR
- Issue date: 2018 Mar 23